Skip to content


  • Poster presentation
  • Open Access

Interleukin 1 blockade with canacinumab for hyperimmunoglobulin D and periodic fever syndrome

  • 1,
  • 1,
  • 1,
  • 2 and
  • 2
Pediatric Rheumatology201412 (Suppl 1) :P270

  • Published:


  • Status Epilepticus
  • Considerable Improvement
  • Recurrent Episode
  • Febrile Seizure
  • Final Dose


Hyperimmunoglobulinemia D and periodic fever syndrome (HIDS; MIM# 260920) is a rare autosomal recessive autoinflammatory condition caused by mutations in the MVK gene, which encodes for mevalonate kinase. There is no standard treatment for HIDS.


We report on a 2 year-old Austrian boy with recurrent episodes of fever, febrile seizures, arthralgias, and splenomegaly. Rash and abdominal pain were also seen occasionally. During attacks an acute-phase response was detected. Clinical and laboratory improvement was seen between attacks. These findings led to the tentative diagnosis of HIDS.


Sequencing of the MVK gene showed a homozygous c.1129G>A (p.Val377Ile, also known as V377I) mutation in the child, while the healthy non-consanguineous parents were heterozygous. The mutation is known to be associated with HIDS.


Therapy with nonsteroidal anti-inflammatory drugs during attacks had poor benefit. A further febrile episode resulted in a status epilepticus. Treatment with canakinumab was initiated and a final dose of 4 mg/kg every 4 weeks resulted in the disappearance of febrile attacks and a considerable improvement of patient´s quality of life during a 6-month follow-up period. The drug has been well tolerated, and no side effects were observed.


Treatment with canakinumab is a therapeutical option for patients with HIDS.

Disclosure of interest

None declared.

Authors’ Affiliations

Pediatrics, Medical University Innsbruck, Innsbruck, Austria
Human Genetics, Medical University Innsbruck, Innsbruck, Austria